EDGAR Verified
Primary Source · SEC.gov

CCA Longevity Fund IV (US III), LLC

CIK 0001954723Fund Vehicle2023 vintage506(b), 3(c)

Raised

$28M

Investors

8

Min Invest

$250,000

AltStreet Analysis

·

Generated from EDGAR primary sources

CCA Longevity Fund IV (US III), LLC is a Delaware-domiciled pooled investment fund focused on longevity biotech, filed as an amended Form D on March 1, 2023. The fund has raised $28.3 million from 8 investors under Rule 506(b) and Section 3(c) exemptions, with a $250,000 minimum investment. William Corry is listed as director.

This longevity biotech fund employs a 506(b) private placement structure with a $250,000 minimum, positioning it in the accessible end of institutional-grade alternative investments. The investor count of 8 for $28.3 million raised suggests an average commitment of approximately $3.5 million per participant, consistent with emerging manager or specialized sector funds in the biotech longevity space.

Data Flags

firstSaleDateFirst sale date not disclosed on this amended filing despite total raise under $100M
statesOfSolicitationNo states of solicitation specified, unusual for a 506(b) offering which requires pre-existing relationships

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001954723
Entity NameCCA Longevity Fund IV (US III), LLC
Exemption506(b), 3(c)
First Sale Date
Filing DateMarch 1, 2023
Accession Number0001954723-23-000001
Total Amount Sold$28M
Total Investors8
Minimum Investment$250,000
Securities TypePooled Investment Fund
State of IncorporationNot specified
Amendment CountOriginal filing only

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

William Corry

Director · Vero Beach, FL

Is this your offering?

Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.